Northeast Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Northeast Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$575K	Buy	+1,157	New	+$513K	0.02%	139

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Northeast Investment Management's VRTX Position: Q2 2026 in Review

Northeast Investment Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1,157 shares worth $575K. The stake represents 0.02% of the portfolio and ranks #139 among its holdings.

484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Northeast Investment Management held 1,157 shares of Vertex Pharmaceuticals worth $575K as of Q2 2026.
Vertex Pharmaceuticals was a new Northeast Investment Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of Northeast Investment Management's portfolio in Q2 2026, its #139 holding.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Northeast Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.